AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01387880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan.
Study NCT01387880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 1.66 mg per day up to 7½ mg per day
Study NCT01387880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 1.66 mg per day up to 7½ mg per day
Study NCT01200212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane, Avastin
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Study NCT01200212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane, Avastin, Xeloda
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Study NCT03386903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ture acupuncture
Description: Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months.
Study NCT03386903 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Description: Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
Study NCT02394782 — intervention group
Intervention type: DEVICE
Intervention: RebiSmart®2.0
Description: Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
Study NCT02394782 — intervention group
Intervention type: DEVICE
Intervention: MSdialog™
Description: Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
Study NCT01608074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical fimbriectomy
Description: Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)
Study NCT01608074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histopathology SEE-FIM
Description: Anatomopathological study of surgical specimens
Study NCT02507297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP)
Description: Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
Study NCT00702520 — intervention group
Intervention type: DRUG
Intervention: Corifollitropin alpha (MK-8962, Org 36286) 100 ug
Description: Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
Study NCT00702520 — intervention group
Intervention type: DRUG
Intervention: Corifollitropin alpha (MK-8962, Org 36286) 150 ug
Description: Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
Study NCT03822533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapist as primary assessor
Description: Physiotherapist diagnose and treat the patient.
Study NCT03822533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physician as primary assessor
Description: Physician diagnose and treat the patient.
Study NCT01928368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 282
Description: Single dose either subcutaneously or intravenously on day 1.
Study NCT01928368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 282 Matching Placebo
Description: Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
Study NCT01088932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRX246
Description: capsules
Study NCT01088932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: capsules
Study NCT04323813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Detection and quantification of EMT-transcription factor mRNA levels in blood
Study NCT03025763 — intervention group
Intervention type: OTHER
Intervention: Craniosynostosis Network Environmental Survey
Description: Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
Study NCT03025763 — intervention group
Intervention type: OTHER
Intervention: 2D/3D Photography
Description: Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
Study NCT03025763 — intervention group
Intervention type: PROCEDURE
Intervention: Buccal Swab Cell Sampling
Description: One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
Study NCT03025763 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
Study NCT03025763 — intervention group
Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as possible). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
Study NCT03025763 — intervention group
Intervention type: PROCEDURE
Intervention: Tissues from a Clinically Indicated Procedure
Description: In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
Study NCT03025763 — intervention group
Intervention type: PROCEDURE
Intervention: Pre-operative CT Scan Image Files.
Description: Optional for those who had a previous CT scan for a prior traumatic event.
Study NCT01040637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose level 2
Study NCT02268201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral
Study NCT02268201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: oral
Study NCT00760929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv 9mg/kg weekly
Study NCT00760929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv 16mg/kg every 3 weeks
Study NCT00760929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: iv 9mg/kg weekly
Study NCT00760929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: iv 16mg/kg every 3 weeks
Study NCT00760929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily
Study NCT00760929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily
Study NCT04110613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: noFast: Start tube feeds within 1 hour of procedure
Description: Earliest possible initiation of tube feeding after bedside PEG tube procedure.
Study NCT04437654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation group(Apixaban group)
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Study NCT01923259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg
Study NCT01923259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg
Study NCT01040637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose level 3
Study NCT01040637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Dose Level 4
Study NCT01040637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Ascending doses
Study NCT01040637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending doses
Study NCT02156037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Dashboard Intervention
Description: The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
Study NCT02156037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diabetes Care
Description: The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
Study NCT01406379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic clip
Description: Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
Study NCT01406379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Detachable snare
Description: In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
Study NCT00333983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Upper Extremity Neurorehabilitation
Description: Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
Study NCT00333983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Upper Extremity Exercise Group
Description: Upper extremity stretching, skateboard reaching activities, and arm ergometer
Study NCT02118116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applied Suicide Intervention Skills Training
Description: Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
Study NCT00702520 — intervention group
Intervention type: DRUG
Intervention: Triptorelin
Description: Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
Study NCT02738567 — intervention group
Intervention type: PROCEDURE
Intervention: patients undergoing surgery or medical procedure
Study NCT00324870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00324870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00002574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00002574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Study NCT02634411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 days of effective antibiotic treatment
Description: Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days.
Study NCT02634411 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 15 days of effective antibiotic treatment
Description: Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days.
Study NCT00702520 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant follicle stimulating hormone (recFSH)
Description: From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
Study NCT03830047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nd yag laser
Description: nd yag laser will be applied on the vulval warts
Study NCT00217854 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopic
Description: Bronchoscopic procedure
Study NCT04037566 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: XYF19 CAR-T cell
Description: Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
Study NCT04037566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
Study NCT00702520 — intervention group
Intervention type: BIOLOGICAL
Intervention: Human chorionic gonadotprophin (hCG).
Description: HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
Study NCT03999710 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
Study NCT03999710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A dose of 1500mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
Study NCT03644277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermitted Hypoxia
Description: Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
Study NCT03644277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute Intermitted Hypoxia
Description: Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
Study NCT03644277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermitted Hypoxia
Description: Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
Study NCT03644277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massed Practise
Description: Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve >100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded.
Study NCT03644277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapael Glove
Description: The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
Study NCT03644277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapael Glove
Description: The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
Study NCT03916159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrauterine placental transfusion (Intervention group)
Description: At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
Study NCT03916159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping (Control group)
Description: At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
Study NCT00525915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15.
Study NCT03836261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib,
Study NCT00525915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15
Study NCT00525915 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment every weekday for 5 weeks.
Study NCT00525915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.